Loading...
•
Mar 31, 2021
Omnicell Q1 2021 Earnings Report
Reported record revenues and exceeded first quarter guidance.
Key Takeaways
Omnicell announced strong first quarter results, achieving record revenue of $252 million, a 10% increase year-over-year. GAAP net income per diluted share was $0.30, and non-GAAP net income per diluted share was $0.83. The company also added new long-term, sole-source partnership agreements with Top 300 U.S. Health Systems.
Delivered an exceptionally strong first quarter, exceeding guidance and achieving record revenue.
Made tremendous progress advancing the vision of the autonomous pharmacy.
Saw robust and growing demand for solutions as providers work to optimize and automate pharmacy workflows.
Increased the number of long-term, sole-source agreements with top 300 U.S. health systems.
Revenue by Segment
Forward Guidance
For the second quarter of 2021, Omnicell expects total revenues to be between $265 million and $270 million. The Company expects product revenues to be between $192 million and $195 million, and service revenues to be between $73 million and $75 million. The Company expects second quarter 2021 non-GAAP EBITDA to be between $53 million and $56 million. The Company expects second quarter 2021 non-GAAP earnings to be between $0.80 and $0.85 per share.
Positive Outlook
- Total revenues to be between $265 million and $270 million.
- Product revenues to be between $192 million and $195 million.
- Service revenues to be between $73 million and $75 million.
- Non-GAAP EBITDA to be between $53 million and $56 million.
- Non-GAAP earnings to be between $0.80 and $0.85 per share.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...